Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wekken, A J van der
OSIRIS, NCT04737382: Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.	Recruiting	N/A	200	Europe	biopsy, ctDAN analysis	The Netherlands Cancer Institute, AstraZeneca	Non-small-cell Lung Carcinoma	08/24	08/24